Consistent with these findings, PP2A is repressed in NSCLC by inactivating mutations, overexpression of PP2A inhibitory proteins or post-translational modifications [14], but in most cases the underlying molecular mechanisms are unknown. The gene discussed is PTPA; the disease is non-small cell lung carcinoma.